Fulcrum lost approximately 50% of its value in a single session after disclosing on June 1, 2026, that the FDA had raised class-wide safety concerns about PRC2-targeting agents, leading the Company to discontinue the program of its lead candidate pociredir.
In its 10-K filed February 24, 2026, Fulcrum disclosed insider equity positions totaling over 260,000 shares for certain executives. The stock traded above $20 in the months preceding the June 1, 2026 disclosure and declined to approximately $10 following the announcement.
The 10-K also disclosed a long-term lease commitment of approximately $25.1 million for office and laboratory space, and referenced a CAMP4 Therapeutics agreement valued at up to $70 million in milestones plus royalties, with the upfront payment not separately quantified.
To receive more information, please fill out the form.
